James Foster - Virax Biolabs Chairman CEO
| VRAX Stock | USD 1.94 0.06 3.19% |
Insider
James Foster is Chairman CEO of Virax Biolabs Group
| Age | 39 |
| Address | BioCity Glasgow, Lanarkshire, United Kingdom, ML1 5UH |
| Phone | 44 20 7788 7414 |
| Web | https://viraxbiolabs.com |
James Foster Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Foster against Virax Biolabs stock is an integral part of due diligence when investing in Virax Biolabs. James Foster insider activity provides valuable insight into whether Virax Biolabs is net buyers or sellers over its current business cycle. Note, Virax Biolabs insiders must abide by specific rules, including filing SEC forms every time they buy or sell Virax Biolabs'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Foster over three months ago Disposition of 25000 shares by James Foster of Charles River at 250.0 subject to Rule 16b-3 | ||
James Foster over six months ago Acquisition by James Foster of 23741 shares of Charles River subject to Rule 16b-3 | ||
James Foster over a year ago Acquisition by James Foster of 500000 shares of ZeroFox Holdings subject to Rule 16b-3 | ||
James Foster over a year ago Sale by James Foster of 67116 shares of ZeroFox Holdings |
Virax Biolabs Management Efficiency
The company has return on total asset (ROA) of (0.499) % which means that it has lost $0.499 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9598) %, meaning that it created substantial loss on money invested by shareholders. Virax Biolabs' management efficiency ratios could be used to measure how well Virax Biolabs manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.3 in 2024. Return On Capital Employed is likely to rise to -1.16 in 2024. At this time, Virax Biolabs' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 1.2 M in 2024, whereas Total Assets are likely to drop slightly above 3.4 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| Robert Dudley | Transcode Therapeutics | 73 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| Qiyong Liu | Transcode Therapeutics | 60 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| MD MBA | Kiora Pharmaceuticals | 50 | |
| Melissa Tosca | Kiora Pharmaceuticals | N/A | |
| Brian Strem | Kiora Pharmaceuticals | 44 | |
| Anna Moore | Transcode Therapeutics | 62 | |
| Jay Cross | Sonnet Biotherapeutics Holdings | 53 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| MaryJane Rafii | Kiora Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.96 | ||||
| Return On Asset | -0.5 |
Virax Biolabs Group Leadership Team
Elected by the shareholders, the Virax Biolabs' board of directors comprises two types of representatives: Virax Biolabs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Virax. The board's role is to monitor Virax Biolabs' management team and ensure that shareholders' interests are well served. Virax Biolabs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Virax Biolabs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tomasz George, Chief Officer | ||
| Joel Yeung, Accounting Manager | ||
| Nigel MSc, Chief Officer | ||
| Cameron Shaw, COO Director | ||
| James Wang, Head Sourcing | ||
| James Foster, Chairman CEO | ||
| Mark Ternouth, Chief Director | ||
| Jason Davis, Chief Officer | ||
| Lily Fu, Head Chain | ||
| Clement Monteil, Head Development |
Virax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Virax Biolabs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.96 | ||||
| Return On Asset | -0.5 | ||||
| Operating Margin | (42.54) % | ||||
| Current Valuation | 4.8 M | ||||
| Shares Outstanding | 4.34 M | ||||
| Shares Owned By Insiders | 7.06 % | ||||
| Shares Owned By Institutions | 6.06 % | ||||
| Number Of Shares Shorted | 446.54 K | ||||
| Price To Book | 1.52 X | ||||
| Price To Sales | 52.19 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Virax Stock Analysis
When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.